Post-BIO Podcast: Thoughts From The Frontlines

Pink Sheet and Scrip journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

Pink Sheet podcast
Pink Sheet and Scrip journalists talk about key topics at the recent BIO meeting. • Source: Citeline/Shutterstock

Join Scrip editors Mandy Jackson and Mary Jo Laffler and Pink Sheet Senior Writer Sarah Karlin-Smith in this free access audio podcast on the recent BIO International Convention in Boston.

The discussion covers the general mood around the current US economic and policy environment, the dismissal of the US ACIP vaccine panel, the climate for deals and financing, the rise of China’s biopharma industry and other key topics from the meeting.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Time Stamps

0:45 Economic and policy environment in the US.

2:50 BIO leadership surprisingly open about the industry’s challenges, and willingness to call out Trump government.

4:20 Most-favored nation policy proposal: storm in a teacup or existential threat?

7:57 DTC sales: new opportunities to sidestep middlemen? GLP-1s leading the way.

10:52 Impact of FDA staff cuts and changes on regulatory practices and policy, and on biopharma companies.

16:47 Reaction of vaccine companies, health providers, insurers and other stakeholders to ACIP panel dismissal and policy uncertainty.

22:27 Climate for biopharma dealmaking and financing; demand for assets.

27:28 Advice for startups in challenging times.

29:49 China’s biopharma industry in the ascendant.

33:27 Rare diseases policy, regulation and industry focus.

38:15 Priorities for BIO.

More from BIO

Post-BIO Podcast: Thoughts From The Frontlines

Pink Sheet and Scrip journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

Pink Sheet and Scrip journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By 

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.